ATE328905T1 - Igg3 immunogloblin als schutzsmarker gegen viren infektiösen krankheiten und seine verwendungen - Google Patents

Igg3 immunogloblin als schutzsmarker gegen viren infektiösen krankheiten und seine verwendungen

Info

Publication number
ATE328905T1
ATE328905T1 AT03739532T AT03739532T ATE328905T1 AT E328905 T1 ATE328905 T1 AT E328905T1 AT 03739532 T AT03739532 T AT 03739532T AT 03739532 T AT03739532 T AT 03739532T AT E328905 T1 ATE328905 T1 AT E328905T1
Authority
AT
Austria
Prior art keywords
igg3
immunogloblin
infectious diseases
against viruses
marker against
Prior art date
Application number
AT03739532T
Other languages
English (en)
Inventor
Jean-Claude Chermann
Camille Haslin
Oliveira Ricardo De
Original Assignee
Urrma R & D
Urrma Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urrma R & D, Urrma Biopharma filed Critical Urrma R & D
Application granted granted Critical
Publication of ATE328905T1 publication Critical patent/ATE328905T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03739532T 2002-02-15 2003-02-13 Igg3 immunogloblin als schutzsmarker gegen viren infektiösen krankheiten und seine verwendungen ATE328905T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0201960A FR2836146B1 (fr) 2002-02-15 2002-02-15 IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS

Publications (1)

Publication Number Publication Date
ATE328905T1 true ATE328905T1 (de) 2006-06-15

Family

ID=27636232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03739532T ATE328905T1 (de) 2002-02-15 2003-02-13 Igg3 immunogloblin als schutzsmarker gegen viren infektiösen krankheiten und seine verwendungen

Country Status (11)

Country Link
US (2) US7306798B2 (de)
EP (1) EP1476467B9 (de)
AT (1) ATE328905T1 (de)
AU (1) AU2003226884A1 (de)
CY (1) CY1105536T1 (de)
DE (1) DE60305884T2 (de)
DK (1) DK1476467T3 (de)
ES (1) ES2266832T3 (de)
FR (1) FR2836146B1 (de)
PT (1) PT1476467E (de)
WO (1) WO2003068820A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021800A1 (en) * 1995-06-30 2003-01-30 Jean-Claude Chermann Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis
EP2094733A1 (de) * 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4-antikörper
TW200846363A (en) * 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
RU2424530C1 (ru) * 2009-12-18 2011-07-20 Учреждение Российской академии медицинских наук научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова РАМН (НИИВС им. И.И. Мечникова РАМН) Способ серологической диагностики коклюша
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646607B1 (fr) 1989-05-03 1991-08-30 Inst Nat Sante Rech Med Anticorps monoclonaux anti-b2 microglobuline
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
US20030021800A1 (en) 1995-06-30 2003-01-30 Jean-Claude Chermann Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis

Also Published As

Publication number Publication date
WO2003068820A9 (fr) 2004-05-27
EP1476467A1 (de) 2004-11-17
EP1476467B9 (de) 2007-01-03
US20050152910A1 (en) 2005-07-14
FR2836146A1 (fr) 2003-08-22
CY1105536T1 (el) 2010-07-28
DK1476467T3 (da) 2006-10-16
WO2003068820A1 (fr) 2003-08-21
US7306798B2 (en) 2007-12-11
DE60305884T2 (de) 2007-03-01
FR2836146B1 (fr) 2005-01-07
ES2266832T3 (es) 2007-03-01
PT1476467E (pt) 2006-10-31
DE60305884D1 (de) 2006-07-20
US20080286755A1 (en) 2008-11-20
AU2003226884A1 (en) 2003-09-04
EP1476467B1 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
ATE328905T1 (de) Igg3 immunogloblin als schutzsmarker gegen viren infektiösen krankheiten und seine verwendungen
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CR11310A (es) Espiro-Pirrolidinas y su uso contra infeccion por el virus de Hepatitis C (HCV) y por el virus de Inmunodeficiencia Humana (VIH)
CY1109671T1 (el) Αναστολεις της πρωτεασης ns3 του hcv
ATE530561T1 (de) 3-ether- und 3-thioether-substituierte ciclosporinderivate zur behandlung und prävention einer hepatitis-c-infektion
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
CR20120356A (es) Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
WO2007038507A3 (en) Modified 4'-nucleosides as antiviral agents
WO2007084435A8 (en) Methods for treating hepatitis c
UY29266A1 (es) Compuestos de piridazinona
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
ATE498630T1 (de) Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
ATE555794T1 (de) Heilmittel gegen hepatitis
ATE539155T1 (de) Targets und zusammensetzungen zur therapeutischen intervention bei hiv-infektion
GEP20084377B (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
WO2005084315A3 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
BR0308201A (pt) Derivados de quinolina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1476467

Country of ref document: EP

REN Ceased due to non-payment of the annual fee